Abstract
A basic problem in the discovery and development of novel drugs to be used in the treatment of neurological and psychiatric disorders is the absence of relevant in vitro or in vivo animal models that can yield results which can be extrapolated to man. Drug research now benefits from the fast development of functional imaging techniques such as positron emission tomography (PET) which trace radiolabelled molecules directly in the human brain. PET uses molecules that are labelled with short-lived radionuclides and injected intravenously into experimental animals, human volunteers or patients. The most frequent approach is to study how an unlabelled drug inhibits specific binding of a well characterised selective PET radioligand. The alternative direct approach is to radiolabel a new potential drug and to trace its uptake, anatomical distribution and binding in brain. Furthermore, the effects of a novel drug on physiological-biochemical parameters, such as glucose metabolism or blood flow, can also be assessed. The demonstration of quantitative relationships between drug binding in vivo and drug effects in patients is used to validate targets for drug action, to correlate pharmacological and physiological effects, and to optimise clinical treatment.
Keywords: positron emission tomography pet, radioligands, brain receptor binding
Current Pharmaceutical Design
Title: PET Studies with Carbon-11 Radioligands in Neuropsychopharmacological Drug Development
Volume: 7 Issue: 18
Author(s): Christer Halldin, Balazs Gulyas and Lars Farde
Affiliation:
Keywords: positron emission tomography pet, radioligands, brain receptor binding
Abstract: A basic problem in the discovery and development of novel drugs to be used in the treatment of neurological and psychiatric disorders is the absence of relevant in vitro or in vivo animal models that can yield results which can be extrapolated to man. Drug research now benefits from the fast development of functional imaging techniques such as positron emission tomography (PET) which trace radiolabelled molecules directly in the human brain. PET uses molecules that are labelled with short-lived radionuclides and injected intravenously into experimental animals, human volunteers or patients. The most frequent approach is to study how an unlabelled drug inhibits specific binding of a well characterised selective PET radioligand. The alternative direct approach is to radiolabel a new potential drug and to trace its uptake, anatomical distribution and binding in brain. Furthermore, the effects of a novel drug on physiological-biochemical parameters, such as glucose metabolism or blood flow, can also be assessed. The demonstration of quantitative relationships between drug binding in vivo and drug effects in patients is used to validate targets for drug action, to correlate pharmacological and physiological effects, and to optimise clinical treatment.
Export Options
About this article
Cite this article as:
Halldin Christer, Gulyas Balazs and Farde Lars, PET Studies with Carbon-11 Radioligands in Neuropsychopharmacological Drug Development, Current Pharmaceutical Design 2001; 7 (18) . https://dx.doi.org/10.2174/1381612013396871
DOI https://dx.doi.org/10.2174/1381612013396871 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Visual and Quantitative Assessment of COVID-19 Pneumonia on Chest CT: The Relationship with Disease Severity and Clinical Findings
Current Medical Imaging Orphan GPCR Ligands Related to Obesity
Current Medicinal Chemistry - Central Nervous System Agents Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Brachial-Ankle Pulse Wave Velocity in the Measurement of Arterial Stiffness: Recent Evidence and Clinical Applications
Current Hypertension Reviews History and Milestones of Mouse Models of Autoimmune Diseases
Current Pharmaceutical Design Proposing a “Lipemic Index” As a Nutritional and Research Tool
Current Vascular Pharmacology Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Functional Materials Based on Nanoparticle Modified Polypropylene Fibers
Micro and Nanosystems Receptor Dimerization - Rationale for the Design of Bivalent Ligands
Current Topics in Medicinal Chemistry Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation
Current Pharmaceutical Design Recent Patents in Plant Biotechnology: Impact on Global Health
Recent Patents on Biotechnology Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery
Current Drug Targets VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanoparticle-Derived Non-Viral Genetic Transfection at the Blood-Brain Barrier to Enable Neuronal Growth Factor Delivery by Secretion from Brain Endothelium
Current Medicinal Chemistry Sulfonated Carbon/Silica Composites: Highly Efficient Heterogeneous Catalysts for the One-Pot Synthesis of Hantzsch 1,4-dihydropyridines, 2,4,5-trisubstituted Imidazoles and 2-arylbenzimidazoles
Current Catalysis Gene Therapy Approaches to Ataxias
Current Gene Therapy Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry The Salivary miRNome: A Promising Biomarker of Disease
MicroRNA Neuronal Histamine and Histamine Receptors in Food Intake and Obesity
Mini-Reviews in Medicinal Chemistry Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry